The Wolverine Gap
BPC-157 use is rising faster than controlled human evidence. Adoption is a fact worth studying—not proof that the healing claims work.
A note from the press room
What changed—and what did not
BPC-157 remains unapproved by the FDA. Reuters reported on September 15 that the agency had not issued a final decision following a July advisory-committee recommendation concerning pharmacy compounding. Any eventual compounding eligibility would not make BPC-157 an FDA-approved drug or establish efficacy.
The clinical-note record
Observational human evidence—preprint, not peer reviewed: Researchers used language-model-assisted review of clinical notes covering 15.2 million patients and identified 1,039 people with documented BPC-157 use. Newly documented use increased approximately 33-fold from early 2020 to early 2026.
A response direction appeared for only 354 users. Of those, 279 had improvement documented, while 685 of the 1,039 users had no recorded response direction. Half the cohort also had another therapeutic intervention recorded. There was no untreated comparator, standardized product, indication, or outcome assessment. The study describes use and reported experiences; it does not demonstrate efficacy.
Controlled human evidence: No new randomized BPC-157 result was identified. Online claims that BPC-157 or the BPC-157/TB-500 Wolverine Stack reliably repairs tissue, accelerates recovery, or improves performance remain unsupported by controlled human evidence.
What was reported in people
The preprint found possible neuropsychiatric, injection-site or dermatologic, and gastrointestinal events in clinical notes, but passive documentation cannot estimate their true frequency. Among 129 people with a documented discontinuation, 24 had an adverse effect recorded as a reason.
Reuters separately reported ten serious adverse-event reports associated with BPC-157 in the FDA monitoring system since 2021. Such reports identify signals; they do not establish that BPC-157 caused the events.
The oral-macrocycle offering
Confirmed disclosure: Privately held Orbis Medicines and Novo Nordisk A/S announced a multi-target cardiometabolic discovery and licensing agreement worth up to $1.4 billion in upfront and possible milestone payments, plus tiered royalties. Novo will also invest in Orbis. The collaboration concerns orally bioavailable synthetic macrocycles; no specific candidate, target, clinical result, or manufacturer was disclosed.
Dated market record: NVO closed September 16 at $41.71, down 1.93% for the session and 5.23% over five days. Because the Orbis announcement followed on September 17, that movement predates the deal and cannot be attributed to it.
Editorial inference: The agreement demonstrates commercial interest in oral macrocycle technology. It does not validate an unnamed medicine, and “up to $1.4 billion” is not money already paid.
Descriptive market reporting only—not an investment recommendation.
Classification check
No classification change is recommended. BPC-157 remains an unapproved peptide supported primarily by preclinical work and highly limited human observations. The Wolverine Stack remains an unsupported combination.
Read the permanent BPC-157 evidence record → · Read the Wolverine Stack record →
What evidence comes next
Orbis disclosed a platform and partnership, not a named candidate suitable for canon review. BPC-157 requires prospective product-quality work, early-phase safety studies, and controlled human trials before its claims can be reconsidered.
The Wolverine Gap: When Adoption Arrives Before Evidence
- What the clinical-note study measured
- Why documented improvements do not establish efficacy
- Missing responses, stacking, and other confounders
- Adverse-event reports versus proven causation
- Compounding status versus FDA approval
- The controlled studies needed to resolve the claims
Primary and authoritative sources
- BPC-157 clinical-note preprint · September 7, 2026
- Reuters · BPC-157 use, regulation, and adverse-event reports · September 15, 2026
- Orbis Medicines · Novo Nordisk partnership · September 17, 2026
- Reuters · Orbis–Novo deal report · September 17, 2026
- MarketWatch · NVO market data · reviewed September 17, 2026
Conflicts: the manuscript is a preprint. Its authors report employment by nference, which has biopharmaceutical research collaborations. Orbis and Novo have direct financial interests in their announced partnership. Company descriptions and possible future payments are forward-looking.